Agomelatine (S 20098; N(2-(7-methoxy-1-naphthyl)ethyl) acetamide) is a potent agonist of melatonin receptors (Yous et al, 1992; Ying et al, 1996; Conway et al, 2000) and an antagonist of the 5-HT 2C ...

Agomelatine is an antidepressant with a novel mechanism of action. It is a melatonergic agonist for MT1 and MT2 receptors and a serotonin (5-HT) 2C receptor antagonist (Millan et al, 2003; Audinot et ...

A New Drug Class paper published Online First by The Lancet looks at the use of melatonin and its analogues—traditionally used to modify the body's internal clock (circadian system)—in the treatment ...

GlyphAgo achieved therapeutic exposures of agomelatine at doses projected to avoid liver enzyme elevations and reduce or eliminate the need for liver function testing that has previously limited ...

A relationship-based approach to improving the clinical trial experience. This is an ASCO Meeting Abstract from the 2019 ASCO Annual Meeting I. This abstract does not include a full text component.

(HealthDay)—Oral systemic agomelatine has a hypotensive effect that decreases intraocular pressure (IOP) in both eyes of treatment-resistant primary open angle glaucoma (POAG) patients, according to a ...

Please provide your email address to receive an email when new articles are posted on . Agomelatine proved safe and effective in treating adolescents with major depressive disorder who received ...

GlyphAgo is an oral prodrug of agomelatine, a medicine with established clinical efficacy in four out of four previous third-party randomized, placebo-controlled studies in generalized anxiety ...

The Institute was proposing that the forthcoming clinical guideline on depression in adults should include the use of agomelatine, meaning that the termination advice in TA231 would be withdrawn at ...

New data, presented today at the 24 th European College of Neuropsychopharmacology (ECNP) Congress, further highlight the distinctive profile of efficacy of Valdoxan® (agomelatine) in the treatment of ...